Rigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline Agents

When I first covered Rigel Pharmaceuticals (NASDAQ: RIGL ) back in April, I felt that they were considerably undervalued considering their then-recent acquisition of an important lung cancer targeted therapy, in addition to having an important IDH1 inhibitor growingI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your ...